
Sebastian Palmqvist

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6829852/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	10.2	668
2	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature Medicine, 2020, 26, 379-386.	30.7	643
3	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	7.4	640
4	Earliest accumulation of \hat{l}^2 -amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	12.8	596
5	Plasma β-amyloid in Alzheimer's disease and vascular disease. Scientific Reports, 2016, 6, 26801.	3.3	442
6	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.1	371
7	<scp>CSF</scp> A <i>β</i> 42/A <i>β</i> 40 and A <i>β</i> 42/A <i>β</i> 38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	3.7	329
8	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42. JAMA Neurology, 2014, 71, 1282.	9.0	300
9	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
10	Cerebrospinal fluid analysis detects cerebral amyloid-l ² accumulation earlier than positron emission tomography. Brain, 2016, 139, 1226-1236.	7.6	292
11	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.1	288
12	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	9.0	282
13	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nature Communications, 2020, 11, 1683.	12.8	252
14	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	30.7	236
15	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	6.9	228
16	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	6.9	219
17	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
18	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.1	207

#	Article	IF	CITATIONS
19	Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Science Advances, 2020, 6, eaaz2387.	10.3	202
20	Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain, 2021, 144, 3505-3516.	7.6	198
21	Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.1	196
22	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	9.0	176
23	¹⁸ Fâ€AVâ€1451 and CSF Tâ€tau and Pâ€tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	6.9	156
24	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain, 2020, 143, 3234-3241.	7.6	150
25	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain, 2017, 140, 2286-2294.	7.6	149
26	Staging β -Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 2019, 76, 1319.	9.0	149
27	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
28	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	9.0	136
29	The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort. Journal of Alzheimer's Disease, 2017, 59, 893-901.	2.6	133
30	Bloodâ€based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	6.9	122
31	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	12.8	115
32	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.1	96
33	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	11.6	94
34	Soluble Pâ€ŧau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	6.9	90
35	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	11.0	85
36	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85

#	Article	IF	CITATIONS
37	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.1	83
38	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.1	80
39	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
40	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. Translational Psychiatry, 2021, 11, 76.	4.8	78
41	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain, 2021, 144, 2771-2783.	7.6	78
42	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. PLoS ONE, 2012, 7, e38639.	2.5	73
43	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
44	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. International Journal of Geriatric Psychiatry, 2009, 24, 1405-1412.	2.7	72
45	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and pâ€ŧau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.8	72
46	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	9.0	66
47	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	7.6	65
48	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	7.6	65
49	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.1	60
50	Tau PET correlates with different Alzheimer's diseaseâ€related features compared to CSF and plasma pâ€ŧau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	6.9	58
51	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	6.0	57
52	Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	6.2	56
53	Assessing risk for preclinical βâ€amyloid pathology with <i>APOE</i> , cognitive, and demographic information. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 76-84.	2.4	49
54	Accurate risk estimation of βâ€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.8	49

#	Article	IF	CITATIONS
55	Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Nature Communications, 2016, 7, 10918.	12.8	48
56	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cerebral Cortex, 2019, 29, 2173-2182.	2.9	39
57	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	12.8	36
58	Association between Subcortical Lesions and Behavioral and Psychological Symptoms in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2011, 32, 417-423.	1.5	33
59	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. Alzheimer's Research and Therapy, 2014, 6, 41.	6.2	33
60	Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. BMC Neurology, 2013, 13, 140.	1.8	31
61	Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2020, 75, 1191-1201.	2.6	31
62	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and Aβ Pathology in Non-demented Individuals. Frontiers in Aging Neuroscience, 2017, 9, 306.	3.4	30
63	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.1	30
64	A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 29.	6.2	29
65	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. Cerebral Cortex, 2018, 28, 340-349.	2.9	28
66	β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Scientific Reports, 2019, 9, 11180.	3.3	28
67	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
68	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE Îμ4, sex and age. Progress in Neurobiology, 2021, 198, 101904.	5.7	25
69	Testâ€retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's and Dementia, 2023, 19, 797-806.	0.8	24
70	Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.1	22
71	Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middleâ€aged or elderly people. Alzheimer's and Dementia, 2018, 14, 54-61.	0.8	21
72	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	1.3	21

#	Article	IF	CITATIONS
73	Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 113-122.	1.3	20
74	Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia. Current Alzheimer Research, 2012, 9, 257-266.	1.4	17
75	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. Alzheimer's Research and Therapy, 2022, 14, 46.	6.2	17
76	Association of CSF Aβ ₃₈ Levels With Risk of Alzheimer Disease–Related Decline. Neurology, 2022, 98, .	1.1	16
77	Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	3.1	15
78	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimer's Research and Therapy, 2019, 11, 109.	6.2	14
79	Derivation and utility of an AÎ ² -PET pathology accumulation index to estimate AÎ ² load. Neurology, 2020, 95, e2834-e2844.	1.1	14
80	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 30.	6.2	14
81	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 439-446.	1.9	11
82	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. Scientific Reports, 2019, 9, 15417.	3.3	11
83	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. NeuroImage: Clinical, 2020, 27, 102310.	2.7	10
84	Unburdening dementia – a basic social process grounded theory based on a primary care physician survey from 25 countries. Scandinavian Journal of Primary Health Care, 2020, 38, 253-264.	1.5	9
85	A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years. International Psychogeriatrics, 2014, 26, 1493-1500.	1.0	8
86	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	3.6	8
87	The Neuroinflammatory Acute Phase Response in Parkinsonianâ€Related Disorders. Movement Disorders, 2022, 37, 993-1003.	3.9	8
88	Relating Experienced To Recalled breathlessness Observational (RETRO) study: a prospective study using a mobile phone application. BMJ Open Respiratory Research, 2019, 6, e000370.	3.0	7
89	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	1.4	7
90	Biomarker testing in MCI patients—deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	6.2	6

#	Article	IF	CITATIONS
91	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. Scientific Reports, 2021, 11, 19853.	3.3	6
92	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.8	6
93	Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. Brain, 2016, 139, e61-e61.	7.6	5
94	Coping Styles among People with Parkinson's Disease: A Three-Year Follow-Up Study. Behavioral Sciences (Basel, Switzerland), 2020, 10, 190.	2.1	5
95	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new diseaseâ€modifying treatments—EQâ€5D data from the Swedish BioFINDER study. Alzheimer's and Dementia, 2021, 17, 1832-1842.	0.8	5
96	Mild to Moderate Cognitive Impairment Does Not Affect the Ability to Self-Report Important Symptoms in Patients With Cancer: A Prospective Longitudinal Multinational Study (EPCCS). Journal of Pain and Symptom Management, 2020, 60, 346-354.e2.	1.2	4
97	Astrocytic function is associated with both amyloid-β and tau pathology in non-demented <i>APOE ïµ4</i> carriers. Brain Communications, 2022, 4, .	3.3	4
98	Prediction of future Alzheimer's disease dementia using plasma phosphoâ€ŧau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.8	2
99	O1â€07â€01: Diagnostic comparison of regional amyloid PET and different CSF biomarker assays for identifying early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, P140.	0.8	1
100	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA Aβ BIOMARKER ASSAYS. Alzheimer's and Dementia, 2018, 14, P1670.	0.8	1
101	Spatial Distribution of Tau and β-Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes. Neurology, 2021, 96, 191-192.	1.1	1
102	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. Journal of Alzheimer's Disease, 2021, , 1-15.	2.6	1
103	Plasma glial fibrillary acidic protein is an early and specific marker of amyloidâ€Î² pathology in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
104	Associations between longitudinal neuropsychiatric symptoms and biomarkers of betaâ€amyloid, tau, neurodegeneration, and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.8	1
105	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Alzheimer's and Dementia, 2021, 17, .	0.8	1
106	P2-290: BIOMARKERS FOR IDENTIFYING NEURODEGENERATIVE DISORDERS EARLY AND RELIABLY (BIOFINDER): METHODOLOGY AND PRELIMINARY RESULTS OF A NEW LARGE PROSPECTIVE COHORT STUDY. , 2014, 10, P583-P584.		0
107	O2â€08â€06: CSF Analysis Detects Cerebral Bâ€Amyloid Accumulation Earlier than Amyloid Pet. Alzheimer's and Dementia, 2016, 12, P246.	0.8	0
108	[P3–284]: THE MONTREAL COGNITIVE ASSESSMENT: NORMATIVE DATA FROM A LARGE SWEDISH POPULATIONâ€BASED COHORT. Alzheimer's and Dementia, 2017, 13, P1051.	0.8	0

#	Article	IF	CITATIONS
109	[O2–01–02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSSâ€VALIDATED METHOD THAT PREDICTS CEREBRAL βâ€AMYLOIDOSIS. Alzheimer's and Dementia, 2017, 13, P548.	0.8	0
110	P3â€492: THE MISINTERPRETED AGE EFFECT ON COGNITIVE TEST RESULTS: A PRESENTATION OF TEST NORMS FROM PERSONS WITHOUT UNDERLYING PATHOLOGIES. Alzheimer's and Dementia, 2018, 14, P1310.	0.8	0
111	P4â€078: CONCORDEâ€AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1465.	0.8	0
112	O3â€14â€05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION. Alzheimer's and Dementia, 2018, 14, P1061.	0.8	0
113	DTâ€01â€06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS. Alzheimer's and Dementia, 2018, 14, P1667.	0.8	0
114	P1â€430: EFFECTS OF <i>APOE</i> ε4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.8	0
115	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.8	0
116	F1â€04â€01: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P206.	0.8	0
117	P1â€373: βETAâ€AMYLOID AND WHITE MATTER LESIONS ARE INDEPENDENTLY ASSOCIATED WITH HIPPOCAMPA ATROPHY AND REDUCED CORTICAL TEMPORAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P439.	0.8	0
118	O3â€04â€01: ASSOCIATIONS BETWEEN TAU, AÎ ² AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1018.	0.8	0
119	ICâ€Pâ€036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P39.	0.8	0
120	O2â€09â€01: CSF, PLASMA AND MRI BIOMARKER TRAJECTORIES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P641.	0.8	0
121	DTâ€01â€04: DIAGNOSTIC PERFORMANCE OF [¹⁸ F]RO948 PET IN THE SEPARATION OF ALZHEIMER DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	'S 0.8	0
122	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that are impacted by APOE ε4, sex and age but not pathology. Alzheimer's and Dementia, 2020, 16, e040745.	0.8	0
123	Genomeâ€wide polygenic risk scores for identification of gene therapeutic target. Alzheimer's and Dementia, 2020, 16, e040903.	0.8	0
124	Health utility in preclinical and prodromal AD compared to controls: EQ5D data from the Swedish Biofinder Study. Alzheimer's and Dementia, 2020, 16, e041032.	0.8	0
125	Biomarker testing in MCI patients: Deciding who to tap. Alzheimer's and Dementia, 2020, 16, e042735.	0.8	0
126	Ability of tauâ€PET, phosphoâ€ŧau217, NfL and cortical thickness to predict shortâ€ŧerm cognitive decline in early symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
127	Unravelling drivers of age―and betaâ€amyloidâ€related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
128	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. Alzheimer's and Dementia, 2021, 17, .	0.8	0
129	Tau and synaptic biomarkers but not amyloidâ€Ĥ² are associated with cerebral perfusion in the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2021, 17, .	0.8	0
130	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
131	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
132	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid Pâ€ŧau181, Pâ€ŧau217 and Pâ€ŧau231 assays. Alzheimer's and Dementia, 2021, 17, .	0.8	0
133	Amyloidâ $\widehat{\mathfrak{cl}^2}$ accumulation is independently related to executive function in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
134	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. Alzheimer's and Dementia, 2021, 17, .	0.8	0
135	The association between diet in midâ€life and dementia incidence over a 20â€year period. Alzheimer's and Dementia, 2021, 17, .	0.8	0
136	Potential drivers of age―and betaâ€amyloidâ€related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
137	Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation Alzheimer's and Dementia. 2021, 17 Suppl 3, e053556.	0.8	0